Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019; 380: 617-628.

Published: 29th April 2019

Authors: Von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M et al.

Conclusion

Some 1486 women with residual invasive disease at operation after neoadjuvant chemotherapy were included. The use of the new conjugate drug improved three year disease-free survival to 88.3 per cent compared with 77 per cent with trastuzumab alone (P<0.001).

Pubmed Link

Your comments

0 Comments